SCHEMBL5086467

SCHEMBL5086467

COc1cc(NC(C)CCCN)c2nc(C(C)(C)C)ccc2c1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
KDM4E B2RXH2 2/20 0.49
NSD2 O96028 1/20 0.49
MAPT P10636 1/20 0.49
MAOA P21397 13/20 0.47
MAOB P27338 13/20 0.47
CYP1A2 P05177 2/20 0.47
ESR1 P03372 2/20 0.47
PGR P06401 2/20 0.47
HTR1A P08908 2/20 0.47
PTGS1 P23219 2/20 0.47
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
OPRM1 P35372 2/20 0.47
SLC6A3 Q01959 2/20 0.47
ABCB11 O95342 1/20 0.47
ADRB2 P07550 1/20 0.47
CHRM2 P08172 1/20 0.47
ADRB1 P08588 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5080779 0.85 HSP90AA1 (0.53) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL5080488 0.81 HSP90AA1 (0.46) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL5080647 0.80 MAOA (0.66) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL5083233 0.79 HSP90AA1 (0.49) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL6268423 0.79 MEN1 (0.47) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL5083304 0.75 MAOA (0.49) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL4727950 0.75 MAOA (0.44) KDM4ENSD2MAPTMAOAMAOB
SCHEMBL5082859 0.74 MAOA (0.43) KDM4ENSD2MAPTMAOAMAOB
SCHEMBL4730513 0.73 KDM4E (0.68) HSP90AA1HSP90AB1KDM4ENSD2MAPT
SCHEMBL4781180 0.73 HSP90AA1 (0.42) HSP90AA1HSP90AB1KDM4ENSD2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 HSP90AA1 3159/4885HSP90AB1 3066/4885KDM4E 64/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN HSP90AA1 358/4885HSP90AB1 225/4885KDM4E 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.